Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
InMed Pharmaceuticals ( (INM) ) has issued an update.
InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as an anti-inflammatory agent for skin diseases. The research highlights how CBN modulates the endocannabinoid system, showing promise for treating conditions like psoriasis and atopic dermatitis. This development could pave the way for therapeutic and cosmetic applications, underscoring CBN’s role in regulating skin inflammation and offering protective benefits.
Learn more about INM stock on TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
